Research and Markets: Human Vaccine Technologies Market 2014-2018 - Key Insights into the $43 Billion Industry
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3fpxcl/human_vaccine) has announced the addition of the "Human Vaccine Technologies Market" report to their offering.
The global vaccine market projected to rise to $43.5 billion by 2018, growing at a CAGR of 12.65%
Rapid advances in understanding of the immune system and desire of medical community to engineer both preventive and therapeutic vaccines for a wide spectrum of diseases are fueling changes in medicine and in the managed care industry.
The growth of global Vaccine market is partly fuelled scientific breakthroughs such as genome sequencing of infectious pathogens, refined understanding of the immune system and its mechanism of response, followed by significant influx of money from public funding bodies, private charity and commercial organizations. Safety, demonstration of sufficiently high efficacy and lack of a consistent evaluation/development pathway are major stumbling blocks for development of new vaccines.
The application of modern biological technologies and advances in genomics has resulted in novel concepts like reverse vaccinology, DNA vaccines, recombinant subunit vaccines and non-replicating vectors, some of these concepts have already progressed to advanced clinical trials and new products such as the meningococcal and hepatitis B vaccine. Recently, cancer and certain autoimmune disorders have received attention as targets for both prophylactic and therapeutic vaccines.
Key Topics Covered:
1. Executive Summary
3. Market Analysis
4. Vaccine Technologies Market, by End-User
5. Vaccine Technologies Market, by Type
6. Vaccine Technologies Market, by Class
7. Vaccine Technology Market, by Disease Indication
8. Regional Market Analysis
9. Company Developments
10. Major Company Profiles
- Antigen Express, INC.
- Bavarian Nordic
- Glaxo Smithkline PLC
- Liquidia Technologies
- Merck & CO., INC.
- Novartis AG
- Pfizer, INC.
For more information visit http://www.researchandmarkets.com/research/3fpxcl/human_vaccine